German federal government is funding the collaborative project RENACO with 1.6 million euros

Pancreas drug nafamostat an option for COVID-19 treatment?

Press release /

Göttingen (Germany), July 31, 2020. In the face of the pandemic spread of SARS-CoV-2 and the worldwide increase in deaths due to this virus, there is an urgent need for effective drugs and vaccines. To speed up the process, existing drugs that have already been approved for treatment of other conditions are tested for their efficacy against the new coronavirus. Scientists of the German Primate Center (DPZ) – Leibniz Institute for Primate Research in Göttingen (Germany) and the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM in Hannover (Germany) are now receiving 1.6 million euros from the German Federal Ministry of Education and Research (BMBF) for a collaborative project investigating the efficacy of nafamostat.